Exploiting monitoring data in environmental exposure modelling and risk assessment of pharmaceuticals

Environment International

Volumn 73, Issue , 2014, Pages 176-185

  Boxall, A B A ^a   Keller, V D J ^b   Straub, J O ^c   Monteiro, S C ^d   Fussell, R ^d   Williams, R J ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d FOOD AND ENVIRONMENT RESEARCH AGENCY   (United Kingdom)

Author keywords

Active pharmaceutical ingredient; Diclofenac; Ibuprofen; Inverse modelling

Indexed keywords

CATCHMENTS; DRAIN CURRENT; DRUG PRODUCTS; ENVIRONMENTAL IMPACT; MONITORING; SURFACE WATERS;

ACTIVE PHARMACEUTICAL INGREDIENTS; DICLOFENAC; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL QUALITY STANDARDS; EXPOSURE CONCENTRATION; IBUPROFEN; INVERSE MODELLING; PREDICTED NO-EFFECT CONCENTRATIONS;

RISK ASSESSMENT;

ACTIVE PHARMACEUTICAL INGREDIENT; DICLOFENAC; DRUG; IBUPROFEN; SURFACE WATER; UNCLASSIFIED DRUG; WATER POLLUTANT; ATENOLOL; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; FLUOXETINE; FUROSEMIDE; KETOPROFEN; NAPROXEN; SIMVASTATIN; TETRAHYDROLIPSTATIN; TRIMETHOPRIM;

CONCENTRATION (COMPOSITION); DRUG; ENVIRONMENTAL IMPACT; ENVIRONMENTAL MONITORING; ENVIRONMENTAL QUALITY; INVERSE ANALYSIS; RISK ASSESSMENT; SURFACE WATER; WASTEWATER; ENVIRONMENTAL IMPACT ASSESSMENT; HYDROLOGICAL MODELING;

AQUATIC SPECIES; ARTICLE; CATCHMENT; CONCENTRATION (PARAMETERS); ENVIRONMENTAL EXPLOITATION; ENVIRONMENTAL EXPOSURE; MODEL; POLLUTION MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURFACE WATER HYDROLOGY; UNITED KINGDOM; WASTE WATER MANAGEMENT; WATER POLLUTION CONTROL; WATER STANDARD; ANALYSIS; CHEMISTRY; ENVIRONMENTAL MONITORING; EVALUATION STUDY; PROCEDURES; RIVER; THEORETICAL MODEL; WATER POLLUTANT; AQUATIC ENVIRONMENT; DATA ANALYSIS; ECOTOXICITY; LANDSCAPE; PHYSICAL CHEMISTRY; PREDICTION; STATISTICAL ANALYSIS; STATISTICAL MODEL; WATER QUALITY;

ENGLAND; UNITED KINGDOM; WALES;

ENGLAND; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; RIVERS; WALES; WATER POLLUTANTS, CHEMICAL;

EID: 84907320121     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2014.07.018     Document Type: Article

References (103)

1. Anderson P.D., D'Aco V.J., Shanahan P., Chapra S.C., Buzby M.E., Cunningham V.L., et al. Screening analysis of human pharmaceutical compounds in US surface waters. Environ Sci Tech 2004, 38:838-849.
2. Ando T., Nagase H., Eguchi K., Hirooka T., Nakamura T., Miyamoto K., et al. A novel method using cyanobacteria for ecotoxicity test of veterinary antimicrobial agents. Environ Toxicol Chem 2007, 26(4):601-606.
3. Andreozzi R., Raffaele M., Paxeus N. Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere 2003, 50:3019-3030.
4. Ankley G.T., Brooks B.W., Huggett D.B., Sumpter J.P. Repeating history: pharmaceuticals in the environment. Environ Sci Technol 2007, 41:8211-8217.
5. Araujo L., Villa N., Camargo N., Bustos M., Garcia T., de Jesus Prieto A. Persistence of gemfibrozil, naproxen and mefenamic acid in natural waters. Environ Chem Lett 2011, 9:13-18.
6. Ashton D., Hilton M., Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 2004, 333:167-184.
7. Bagley C.M., Bostick F.W., DeVita V.T. Clinical pharmacology of cyclophosphamide. Cancer Res 1973, 33:226-233.
8. Bound J.P., Voulvoulis N. Predicted and measured concentrations for selected pharmaceuticals in UK rivers: Implications for risk assessment. Water Res 2006, 40:2885-2892.
9. Boxall A.B.A. The environmental side effects of medication. EMBO Rep 2004, 5(12):1110-1116.
10. Boxall A.B.A., Fogg L.A., Kay P., Blackwell P.A., Pemberton E.J., Croxford A. Veterinary medicines in the environment. Rev Environ Contam Toxicol 2004, 180:1-91.
11. Boxall A.B.A., Monteiro S.C., Fussell R., Williams R.J., Bruemer J., Greenwood R., et al. Targeted monitoring for human pharmaceuticals in vulnerable source and final waters 2012, Department for Environment, Food and Rural Affairs, London, England.
12. Boxall A.B.A., Rudd M.A., Brooks B.W., Caldwell D.J., Choi K., Hickmann S. Pharmaceuticals and personal care products in the environment: what are the key questions. Environ Health Perspect 2012, 120(9):1221-1229.
13. Breton R., Boxall A.B.A. Pharmaceuticals and personal care products in the environment: regulatory drivers and research needs. QSAR Comb Sci 2003, 22:399-409.
14. Brooks B.W., Richards S.M., Weston J., Turner P.K., Stanley J.K., La Point T.W., et al. Aquatic ecotoxicology of fluoxetine: a review of recent research. Hot spot pollutants: pharmaceuticals in the environment 2005, Academic/Elsevier, New York, USA. D. Dietrich, S. Webb, T. Petry (Eds.).
15. Brun G.L., Bernier M., Losier R., Doe K., Jackman P., Lee H.-B. Pharmaceutically active compounds in Atlantic Canadian sewage treatment plant effluents and receiving waters, and potential for environmental effects as measured by acute and chronic toxicity. Environ Toxicol Chem 2006, 25(8):2163-2176.
16. Bürge I.J., Poiger T., Müller M.D., Buser H.-R. Caffeine, an anthropogenic marker for wastewater contamination of surface waters. Environ Sci Tech 2003, 37:691-700.
17. Buser H.-R., Poiger T., Müller M.D. Occurrence and environmental behaviour of the chiral pharmaceutical drug ibuprofen in surface waters and in wastewater. Environ Sci Tech 1999, 33:2529-2535.
18. Christensen A.M., Markussen B., Baun A., Halling-Sorensen B. Probabilistic environmental risk characterization of pharmaceuticals in sewage treatment plant discharges. Chemosphere 2009, 77(3):351-358.
19. Cleuvers M. Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, naproxen, and acetylsalicylic acid. Ecotoxicol Environ Saf 2004, 59:309-315.
20. Daughton C., Ternes T. Pharmaceuticals and personal care products in the environment: agents of subtle change?. Environ Health Perspect 1999, 107:907-937.
21. De Lorenzo M.E., Fleming J. Individual and mixture effects of selected pharmaceuticals and personal care products on the marine phytoplankton species Dunaliella tertiolecta. Arch Environ Contam Toxicol 2008, 54:203-210.
22. Dorne J.L.C.M. Metabolism, variability and risk assessment. Toxicology 2010, 268:156-164.
23. ECHA Guidance on information requirements and chemical safety assessment. Chapter R.10: characterisation of dose [concentration]-response for environment 2010, ECHA, Helsinki, Finland.
24. EMA Guideline on the environmental risk assessment of medicinal products for human use 2006, European Medicines Agency, London, U.K.
25. Environment Agency Development of the integrated water resources and water quality modelling system 2004, Environment Agency, Bristol, England.
26. EQS-TGD Common implementation strategy for the water framework directive (2000/60/EC). Technical guidance for deriving environmental quality standards: guidance Document No. 27 2011, European Commission, Brussels.
27. Eurostat Population in Europe 2012, European Union Statistics Office, Brussels.
28. Ferrari B., Paxeeus N., Lo Giudice R., Pollio A., Garric J. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotoxicol Environ Saf 2003, 55:359-370.
29. Ferrari B., Mons R., Vollat B., Fraysse B., Paxeus N., Lo Giudice R., et al. Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?. Environ Toxicol Chem 2009, 23(5):1344-1354.
30. Fono L.J., Kolodziej E.P., Sedlak D.L. Attenuation of wastewater-derived contaminants in an effluent-dominated river. Environ Sci Technol 2006, 40:7257-7262.
31. Garcia-Ac A., Segura P.A., Gagnon C., Sauvé S. Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extraction liquid chromatography coupled to polarity-switching electrospray tandem mass spectrometry. J Environ Monit 2009, 11:830-838.
32. Gros M., Petrovič M., Ginebreda A., Barceló D. Removal pf pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environ Int 2010, 36:15-26.
33. GSK Safety datasheet: Alli 2008, GSK, Brentford, Middlesex, UK.
34. Han S., Choi K., Kim J., Ji K., Kim S., Ahn B., et al. Endocrine disruption and consequences of chronic exposure to ibuprofen in Japanese medaka (Oryzias latipes) and freshwater cladocerans Daphnia magna and Moina macrocopa. Aquat Toxicol 2010, 98:256-264.
35. Hannah R., D'Aco V.J., Anderson P.D., Buzby M.E., Caldwell D.J., Cunningham V.L. Exposure assessment of 17α-ethinylestradiol in surface waters of the United States and Europe. Environ Toxicol Chem 2009, 28(12):2725-2732.
36. Heberer T., Reddersen K., Mechlinski A. From municipal sewage to drinking water: fate and removal of pharmaceutical residues in the aquatic environment in urban areas. Water Sci Technol 2002, 46(3):81-88.
37. Hilton M.J., Thomas K.V., Ashton D. Targeted monitoring programme for pharmaceuticals in the aquatic environment 2003, Environment Agency, Bristol, England.
38. Hirsch R., Ternes T., Heberer K., Kratz K. Occurrence of antibiotics in the aquatic environment. Sci Total Environ 1999, 225:109-118.
39. Hoeger B., Kollner B., Dietrich D.R., Hitzfeld B. Water-borne diclofenac affects kidney and gill integrity and selected immune parameters in brown trout (Salmo trutta f. fario). Aquat Toxicol 2005, 75:53-64.
40. IMS Health Global product strategy; IMS MIDAS in PADDS. Subscription database 2012, IMS Health Ltd, Danbury, USA.
41. Isidori M., Lavorgna M., Nardelli A., Parrella A., Previtera L., Rubino M. Ecotoxicity of naproxen and its phototransformation products. Sci Total Environ 2005, 348:93-101.
42. Janna H., Scrimshaw M.D., Williams R.J., Churchley J., Sumpter J.P. From dishwasher to tap? Xenobiotic substances benzotriazole and tolyltriazole in the environment. Environ Sci Technol 2011, 45(9):3858-3864.
43. Johnson A.C., Dumont E., Williams R.J., Oldenkamp R., Cisowska I., Sumpter J.P. Do Concentrations of ethinylestradiol, estradiol, and diclofenac in European Rivers exceed proposed EU environmental quality standards?. Environ Sci Technol 2013, 47(21):12297-12304.
44. Kasprzyk-Hordern B., Baker D.R. Enantiomeric profiling of chiral drugs in wastewater and receiving waters. Environ Sci Technol 2012, 46:1681-1691.
45. Kasprzyk-Hordern B., Dinsdale R.M., Guwy A.J. Multi-residue method for the determination of basic/neutral pharmaceuticals and illicit drugs in surface water by solid-phase extraction and ultra performance liquid chromatography-positive electrospray ionisation tandem mass spectrometry. J Chromatogr A 2007, 1161:132-145.
46. Kasprzyk-Hordern B., Dinsdale R.M., Guwy A.J. The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters. Water Res 2009, 43:363-380.
47. Kasprzyk-Hordern B., Dinsdale R.M., Guwy A.J. The occurrence of pharmaceuticals and personal care products, endocrine disruptors and illicit drugs in South Wales, UK. Water Res 2008, 42:3498-3518.
48. Key P.B., Hoguet J., Chung K.W., Venturell J.J., Pennington P.L., Fulton M.H. Lethal and sublethal effects of simvastatin, irgarol, and PBDE-47 on the estuarine fish, Fundulus heteroclitus. J Environ Sci Health B 2009, 44(4):379-382.
49. Kim Y., Choi K., Jung J., Park S., Kim P.-G., Park J. Aquatic toxicity of acetaminophen, carbamazepine, cimetidine, diltiazem and six major sulfonamides, and their potential ecological risks in Korea. Environ Int 2007, 33:370-375.
50. Kolpin D., Furlong E., Meyer M., Zaugg S., Barber L., Buxton H. Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999-2000: a national reconnaissance. Environ Sci Technol 2002, 32:1202-1211.
51. Küster A., Alder A.C., Escher B.I., Duis K., Fenner K., Garric J., et al. Environmental risk assessment of human pharmaceuticals in the European Union: a case study with the β-blocker atenolol. Integr Environ Assess Manag 2010, 6(Suppl. 1):514-523.
52. Kwon J.-W., Armbrust K. Laboratory persistence and fate of fluoxetine in aquatic environments. Environ Toxicol Chem 2006, 25(10):2561-2568.
53. Lam M.W., Young C.J., Brain R.A., Johnson D.J., Hanson M.A., Wilson C.J. Aquatic persistence of eight pharmaceuticals in a microcosm study. Environ Toxicol Chem 2004, 23(6):1431-1440.
54. Leclercq M., Mathieu O., Gomez E., Casellas C., Fenet H., Hillaire-Buys D. Presence and fate of carbamazepine, oxcarbazepine, and seven of their metabolites at wastewater treatment plants. Arch Environ Contam Toxicol 2009, 56:408-415.
55. Lee H.-B., Peart T.E., Svoboda M.L., Backus S. Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples. Chemosphere 2009, 77:1285-1291.
56. Letzel M., Metzner G., Letzel T. Exposure assessment of the pharmaceutical diclofenac based on long-term measurements of the aquatic input. Environ Int 2009, 35:363-368.
57. Lienert J., Güdel K., Escher B.I. Screening method for ecotoxicological hazard assessment of 42 pharmaceuticals considering human metabolism and excretory Routes. Environ Sci Technol 2007, 41:4471-4478.
58. Lister A., Regan C., Van Zwol J., Van Der Kraak G.J. Inhibition of egg production in zebrafish by fluoxetine and municipal effluents: a mechanistic perspective. Aquat Toxicol 2009, 95:320-329.
59. Memmert U., Peither A., Burri R., Weber K., Schmidt T., Sumpter J.P., et al. Diclofenac: new data on chronic toxicity and bioconcentration in fish. Environ Toxicol Chem 2013, 32:442-452.
60. Metcalfe C.D., Alder A.C., Halling-Sørensen B., Krogh K., Fenner K., Larsbo M., et al. Exposure assessment methods for veterinary and human-use medicines in the environment: PEC vs MEC comparisons. Pharmaceuticals in the Environment 2008, Springer, Berlin Heidelberg, Germany. 2nd ed. K. Kümmerer (Ed.).
61. Monteiro S.C., Boxall A.B.A. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 2010, 202:53-154.
62. Murray-Smith R.J., Coombe V.T., Grönlund M.H., Waern F., Baird J.A. Managing emissions of active pharmaceutical ingredients from manufacturing facilities: an environmental quality standard approach. Integr Environ Assess Manag 2012, 8(2):320-330.
63. Musson S.E., Townsend T.G. Pharmaceutical compound content of municipal solid waste pharmaceutical compound content of municipal solid waste. J Hazard Mater 2009, 162:730-735.
64. Nalecz-Jawecki G. Evaluation of the in vitro biotransformation of fluoxetine with HPLC, mass spectrometry and ecotoxicological tests. Chemosphere 2007, 70:29-35.
65. Oakes K.D., Coors A., Escher B.I., Fenner K., Garric J., Gust M. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: case study using the European risk assessment framework. IEAM 2010, 6(1):524-539.
66. Ort C., Hollender J., Schaerer M. Model-based evaluation of reduction strategies for micropollutants from wastewater treatment plants in complex river networks. Environ Sci Technol 2009, 43(9):3214-3220.
67. Paffoni C., Welte B., Gousailles M., Montiel A. Nouvellem molécules mises en cause par les directives européennes: de la station d'épuration à l'usine de traitement d'eau potable. Eur J Water Qual 2006, 37(1):21-38.
68. Park S., Choi K. Hazard assessment of commonly used agricultural antibiotics on aquatic ecosystems. Ecotoxicology 2008, 17:526-538.
69. Paxéus N. Removal of selected non-steroidal anti-inflammatory drugs (NSAIDs), gemfibrozil, carbamazepine, β-blockers, trimethoprim and triclosan in conventional wastewater treatment plants in five EU countries and their discharge to the aquatic environment. Water Sci Technol 2004, 50(5):253-260.
70. Piecha M., Sarakha M., Trebse P., Kocar D. Stability studies of cholesterol lowering statin drugs in aqueous samples using HPLC and LC-MS. Environ Chem Lett 2010, 8:185-191.
71. Pistocchi A., Marinov D., Pontes S., Gawlik B.M. Continental scale inverse modeling of common organic water contaminants in European Rivers. Environ Pollut 2012, 162:159-167.
72. Price O.R., Williams R.J., van Egmond R., Wilkinson M.J., Whelan M.J. Predicting accurate and ecologically relevant regional scale concentrations of triclosan in rivers for use in higher-tier aquatic risk assessments. Environ Int 2010, 36:521-526.
73. Price O.R., Williams R.J., Zhang Z., van Egmond R. Modelling concentrations of decamethylcyclopentasiloxane in two UK rivers using lf2000-wqx. Environ Pollut 2010, 158(2):356-360.
74. Roberts P.H., Bersuder P. Analysis of OSPAR priority pharmaceuticals using high-performance liquid chromatography-electrospray ionisation tandem mass spectrometry. J Chromatogr A 2006, 1143:143-150.
75. Roberts P.H., Thomas K.V. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Total Environ 2006, 356:143-153.
76. Rowney N.C., Johnson A.C., Williams R.J. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 2009, 28(12):2733-2743.
77. Runkel R., Chaplin M., Boost G., Segre E., Forchielli E. Absorption, distribution, metabolism and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci 1972, 61:703-708.
78. SCHER Opinion on 'Chemicals and the water framework directive: draft environmental quality standards' diclofenac 2011, SCHER, Brussels, Belgium.
79. Schowanek D., Webb S. Exposure simulation for pharmaceuticals in European surface waters with GREAT-ER. Toxicol Lett 2002, 131:39-50.
80. Schwab B.W., Hayes E.P., Fioric J.M., Mastrocco F.J., Roden N.M., Cragin D. Human pharmaceuticals in US surface waters: a human health risk assessment. Regul Toxicol Pharmacol 2005, 42(3):296-312.
81. Seehusen D.A., Edwards J. Patient practices and beliefs concerning disposal of medications. J Am Board Fam Med 2006, 19:542-547.
82. SFT Initial assessment of eleven pharmaceuticals using the EMEA guideline in Norway 2006, Statens forurensningstilsyn (SFT), Strømsveien, Norway.
83. Sipma J., Osuna B., Collado N., Monclús H., Ferrero G., Comas J. Comparison of removal of pharmaceuticals in MBR and activated sludge systems. Desalination 2010, 250:653-659.
84. Stanley J.K., Ramirez A.J., Chambliss C.K., Brooks B.W. Enantiospecific sublethal effects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate. Chemosphere 2007, 69(1):9-16.
85. Straub J.O. Deterministic and probabilistic environmental risk assessment for diazepam. Pharmaceuticals in the environment; sources, fate, effects and risks 2008, Springer, Heidelberg, Germany. K. Kümmerer (Ed.).
86. Straub J.O., Stewart K.M. Deterministic and probabilistic acute-based environmental risk assessment for naproxen for Western Europe. Environ Toxicol Chem 2007, 26(4):795-806.
87. Ternes T., Bonerz M., Schmidt T. Determination of neutral pharmaceuticals in wastewaters and rivers by LC-ES-tandem MS. J Chromatogr A 2001, 938:175-185.
88. Thomas K.V., Hilton M.J. The occurrence of selected human pharmaceutical compounds in UK estuaries. Mar Pollut Bull 2004, 49:436-444.
89. UKWIR The UKWIR chemicals investigation programme - A mid-programme update 2012, UKWIR, London, UK.
90. Upton R.A., Buskin J.N., Williams R.L., Holford N.H., Riegelman S. Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine. J Pharm Sci 1980, 69(11):1254-1257.
91. Warn A.E., Brew J.S. Mass balance. Water Res 1980, 14(10):1427-1434.
92. Williams R.J., Keller V.D.J., Johnson A.C., Young A.R., Holmes M.G.R., Wells C. A national risk assessment for intersex in fish arising from steroid estrogens. Environ Toxicol Chem 2009, 28(1):220-230.
93. Winter M.J., Lillicrap A.D., Caunter J.E., Schaffner C., Alder A.C., Ramil M. Defining the chronic impacts of atenolol on embryolarval development and reproduction in the fathead minnow (Pimephales promelas). Aquat Toxicol 2008, 86:361-369.
94. Wu Y., Chen D.-H., Kookana R. Aqueous photodegradation of selected antibiotics under different conditions. Energy Procedia 2011, 11:2098-2103.
95. Yamamoto H., Nakamura Y., Moriguchi S., Nakamura Y., Honda Y., Tamura I. Persistence and partitioning of eight selected pharmaceuticals in the aquatic environment: laboratory photolysis, biodegradation, and sorption experiments. Water Res 2009, 43:351-362.
96. Yang L.-H., Ying G.-G., Su H.-C., Strauber J.L., Adams M.S., Binet M.T. Growth-inhibiting effects of 12 antibacterial agents and their mixtures on the freshwater microalga Pseudokirchneriella subcapitata. Environ Toxicol Chem 2008, 27(5):1201-1208.
97. Young A.R., Grew R., Holmes M.G.R. Low flows 2000: a national water resources assessment and decision support tool. Water Sci Technol 2003, 48(10):119-126.
98. Zhang Z.L., Zhou J.L. Simultaneous determination of various pharmaceutical compounds in water by solid-phase extraction-liquid chromatography-tandem mass spectrometry. J Chromatogr A 2007, 1154:205-213.
99. Zhi J., Melia A.T., Eggers H., Joly R., Patel I.H. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995, 35:1103-1108.
100. Zhou J.L., Zhang Z.L., Banks E., Grover D., Jiang J.Q. Pharmaceutical residues in wastewater treatment works effluents and their impact on receiving river water. J Hazard Mater 2009, 166:655-661.
101. Zounkova R., Odradka P., Dolezalova L., Hilscherova K., Marsalek B., Blaha L. Ecotoxicity and genotoxicity assessment of cytistatic pharmaceuticals. Environ Toxicol Chem 2007, 26(10):2208-2214.
102. Zuccato E., Bagnati R., Fioretti F., Natangelo M., Calamari D., Fanelli R. Environmental loads and detection of pharmaceuticals in Italy. Pharmaceuticals in the environment 2001, Springer, Berlin. K. Kümmerer (Ed.).
103. Zuccato E., Castiglioni S., Tettamanti M., Olandese R., Bagnati R., Melis M., et al. Changes in illicit drug consumption patterns in 2009 detected by wastewater analysis. Drug Alcohol Depend 2011, 118(2-3):464-469.